🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Polycystic Kidney Diseases

Imaging Assessments of ARPKD Kidney Disease Progression NCT07201025n/a2 sites📍 Cleveland📍 Philadelphia The Cleveland Clinic Kidney Sodium Functional Imaging NCT05014178n/a1 site📍 London London Health Sciences Centre Research Institute OR Lawson … · Tests: Sodium-23 MRI A Phase 1 Study of Single and Multiple Ascending Doses of GV-100 NCT07788014Phase 11 site📍 Adelaide Gilva Therapeutics Inc. · Tests: GV-100, Placebo Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study NCT04338048n/a4 sites📍 Washington D.C.📍 Rochester📍 New Hyde Park Children's Hospital of Philadelphia RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY NCT07535385n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) NCT04782258Phase 323 sites📍 Washington D.C.📍 Atlanta📍 Chicago Otsuka Pharmaceutical Development & Commercialization, Inc. · Tests: Tolvaptan Suspension, Tolvaptan Tablets Managing Depressive Symptoms in ADPKD NCT07745920NA1 site📍 Rochester Mayo Clinic · Tests: Mayo Clinic-Approved Education, Digital Neuropathy, Capacity Coaching ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT06902558Phase 291 sites📍 Birmingham📍 Huntington Park📍 Los Angeles Calico Life Sciences LLC · Tests: ABBV-CLS-628, Placebo Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease NCT07454174NA1 site📍 Cleveland Richard Fatica · Tests: Ren-Nu and KetoCitra STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease NCT07280585Phase 330 sites📍 Feldkirch📍 Innsbruck📍 Stuttgart University of Cologne · Tests: Dapagliflozin 10 mg, Matching Placebo A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease NCT05478083Phase 22 sites📍 Nijmegen📍 Groningen University Medical Center Groningen · Tests: Leuprorelin Well-Formulated Ketogenic Diet Polycystic Kidney Disease NCT06325644NA1 site📍 Columbus Ohio State University · Tests: Ketogenic Diet, Ketone/Glucose Monitoring, CGM/CKM, Blood Draw, Body Composition Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment NCT06618638NA9 sites📍 Anyang-si📍 Seoul📍 Busan Seoul National University Hospital · Tests: Shared decision making model, Usual Care ARPKD Database Study NCT01401998n/a6 sites📍 Washington D.C.📍 Atlanta📍 Boston Children's Hospital of Philadelphia Genetics in the Progression of Nephropathies NCT06416761n/a1 site📍 Milan Ospedale San Raffaele · Tests: genetic polymorphisms Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases NCT05996731NA1 site📍 Ranica Mario Negri Institute for Pharmacological Research · Tests: Skin biopsy Analysis of Patients With Autosomal Dominant Polycystic Kidney NCT06759142n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT04344769n/a1 site📍 Rochester Mayo Clinic Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease NCT07228364Phase 115 sites📍 Birmingham📍 Loma Linda📍 Jacksonville AstraZeneca · Tests: AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B Early PKD Observational Cohort Study NCT02936791n/a3 sites📍 Chicago📍 Kansas City📍 Kansas City University of Kansas Medical Center Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease NCT07260071n/a1 site📍 London King's College London Glucagon-Like Peptide-1 Receptor Agonist in ADPKD NCT06582875Phase 21 site📍 Aurora University of Colorado, Denver · Tests: Tirzepatide, Placebo Amnioinfusion for Fetal Renal Failure NCT06728228NA1 site📍 Dallas Fetal Care Center, PLLC · Tests: Amnioinfusion PKD Clinical and Translational Core Study NCT01873235n/a1 site📍 Baltimore University of Maryland, Baltimore Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 NCT06714006Phase 112 sites📍 Southport📍 Concord📍 Liverpool PYC Therapeutics · Tests: PYC-003 NOX4 and Related Biomarkers in ADPKD NCT04630613n/a1 site📍 Rochester Mayo Clinic A Prospective Observational Study of Foam Sclerotherapy . NCT04111692n/a1 site📍 Rochester Mayo Clinic Somatosensory Phenotyping of ADPKD NCT06970028n/a1 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Quantitative Sensory Testing, Questionnaires regarding pain and quality of life Polycystic Kidney Disease Data Repository NCT00792155n/a1 site📍 New York The Rogosin Institute
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy